A Phase 3 interventional study of Etoposide + cisplatin and Irinotecan + cisplatin in Small Cell Lung Carcinoma, sponsored by Pfizer. Completed at 68 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-02-18.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing etoposide in Small Cell Lung Carcinoma — 9 open to participants now, 11 under way, 1 of them phase 3. Etoposide · Small Cell Lung Carcinoma.
Among the 44 studies testing etoposide in Small Cell Lung Carcinoma, this one is the 2nd largest by enrollment, is the only one that started in 2002, is one of 9 in phase 3, and was the 9th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →9 of the 44 studies testing etoposide in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 39 more countries
Ages 18+
Qian Chu · Sites in China
Ages 18+
Sehhoon Park · Sites in Korea, Republic of
Ages 19+
Anhui Provincial Cancer Hospital · Sites in China
Ages 18+
Gruppo Oncologico Italiano di Ricerca Clinica · Sites in Italy
Ages 18+
By country, each count listing its studies:
Etoposide: first FDA approval 1983 (VEPESID). What it is approved for, and how studies give it, is on its page →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 28 · Phase 3 9 · Phase 4 1
First in 1998; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 485 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 59 across the 44 interventional studies. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 44 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
12 studies in Small Cell Lung Carcinoma by Pfizer: 4 open now, 5 under way, 1 of them phase 3. Of 7 finished, 6 (86%) have results posted.
Among the 12 studies in Small Cell Lung Carcinoma by Pfizer, this one is the 3rd largest by enrollment, is the only one that started in 2002, is the only one in phase 3, and was the 1st registered.
Pfizer’s Small Cell Lung Carcinoma studies by the year they started, since 2002.
3 of the studies testing etoposide in Small Cell Lung Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838208Anhui Provincial Cancer HospitalTislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC | 2027-03-01 |
| NCT06830694Sehhoon ParkClinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment | 2027-03-31 |
| NCT06449209BioNTech SESafety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 44 studies testing etoposide in Small Cell Lung Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 12 in Small Cell Lung Carcinoma:
This tab as a report to print or save as PDF → With an account.
To compare the effects of irinotecan hydrochloride with cisplatin to the "standard" regimen etoposide plus cisplatin on overall survival, in chemotherapy-naive patients with newly diagnosed Extensive Disease-Small Cell Lung Cancer (ED-SCLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Etoposide + cisplatin
Drug: Irinotecan + cisplatin
Drug pages: Etoposide · Cisplatin
etoposide 100 mg/m2 days 1, 2 and 3 cisplatin 80 mg/m2 day 1 3 week cycle
Drug pages: Irinotecan · Cisplatin
irinotecan 65 mg/m2 day 1 and 8 cisplatin 80mg/m2 day 1 3 week cycle
Overall Survival (OS) for the Full Analysis Population (FAP)
OS was defined as the time from date of randomization to date of death due to any cause. For a subject not expiring, the OS time was censored on the last date of contact that they were known to be alive. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.
Time frame: Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment)
Overall Survival for the Per Protocol (PP) Population
OS was defined as the time from date of randomization to date of death due to any cause. For a subject not expiring, the OS time was censored on the last date of contact that they were known to be alive. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.
Time frame: Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment)
Number of Subjects With Overall Confirmed Response
Objective disease response = subjects with confirmed complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target lesions. A PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Time frame: Baseline to first documentation of confirmed response (every 9 weeks for up to 6 months on study treatment and every 2 months in follow up until progression)
Duration of Response (DR)
DR was defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.
Time frame: Baseline to first documentation of confirmed response (every 9 weeks for up to 6 months on study treatment and every 2 months in follow up until progression)
Time to Tumor Progression (TTP)
TTP was defined as the time from date of randomization to the date of the first documentation of tumor progression. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.
Time frame: Baseline to date of progression (every 9 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment until progression)
European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30)
The EORTC QLQ-C30 scales include 5 functional scales (physical, role, cognitive, emotional, and social), a global health status/QL scale and 9 symptom scales: nausea and vomiting, pain, fatigue, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties. All scales and single-item measures range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, for the global health status/QL represents a high QL (better patient state), and for a symptom scale/item represents a high level of symptomatology/problems (worse patient state).
Time frame: Baseline, at every cycle (Day -1, Day 1 of cycle before treatment), at the end of the treatment, and every 2 months during follow-up
Tumor Related Symptoms (Pain, Dyspnea, Cough, Hemoptysis, Weight, and the Use of Opioids and Non-Opioids Analgesics)
Improvement of ≥ 1 tumor related symptom = clinical benefit responder. Pain improvement = decrease of ≥ 1 National Cancer Institute (NCI) grade from baseline of ≥ 1 symptom of NCI pain category, without pain symptom worsening. Cough, dyspnea and hemoptysis improvement = decrease of ≥ 1 NCI grade from baseline. Positive weight change ≥ 5 percent gain from baseline. Positive analgesic consumption = change from baseline from opioid to non-opioid category.
Time frame: Every 3 weeks for up to 6 months on study treatment
Enrollment of Cohort 1 was terminated early per protocol amendment (29 September 2003). With limited number of subjects in Cohort 1, the efficacy analysis was exploratory. The amendment reduced Irinotecan dose from 80 to 65 mg/m2. With the study powered for Overall Survival in subjects recruited thereafter (Cohort 2) efficacy analysis is reported.
| Milestone | Irinotecan + Cisplatin (Cohort 1) | Etoposide + Cisplatin (Cohort 1) | Irinotecan + Cisplatin (Cohort 2) | Etoposide + Cisplatin (Cohort 2) |
|---|---|---|---|---|
| Started | 39 | 39 | 0 | 0 |
| Received treatment | 39 | 38 | 0 | 0 |
| Completed | 25 | 22 | 0 | 0 |
| Not completed | 14 | 17 | 0 | 0 |
| Withdrew: Adverse event | 8 | 4 | 0 | 0 |
| Withdrew: Death | 5 | 2 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 6 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 4 | 0 | 0 |
| Withdrew: Randomized but not treated | 0 | 1 | 0 | 0 |
| Milestone | Irinotecan + Cisplatin (Cohort 1) | Etoposide + Cisplatin (Cohort 1) | Irinotecan + Cisplatin (Cohort 2) | Etoposide + Cisplatin (Cohort 2) |
|---|---|---|---|---|
| Started | 0 | 0 | 203 | 204 |
| Received treatment | 0 | 0 | 202 | 203 |
| Completed | 0 | 0 | 97 | 111 |
| Not completed | 0 | 0 | 106 | 93 |
| Withdrew: Adverse event | 0 | 0 | 42 | 30 |
| Withdrew: No longer required study treatment | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 4 |
| Withdrew: Death | 0 | 0 | 20 | 12 |
| Withdrew: Progressive disease | 0 | 0 | 20 | 27 |
| Withdrew: Withdrawal by subject | 0 | 0 | 13 | 12 |
| Withdrew: Other | 0 | 0 | 7 | 6 |
| Withdrew: Randomized but not treated | 0 | 0 | 1 | 1 |
OS was defined as the time from date of randomization to date of death due to any cause. For a subject not expiring, the OS time was censored on the last date of contact that they were known to be alive. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.
| months | Irinotecan + Cisplatin (Cohort 1) | Etoposide + Cisplatin (Cohort 1) | Irinotecan + Cisplatin (Cohort 2) | Etoposide + Cisplatin (Cohort 2) |
|---|---|---|---|---|
| Overall Survival (OS) for the Full Analysis Population (FAP) | — | — | 10.2177 (8.9692 to 11.6632) | 9.6591 (8.9363 to 11.0719) |
Objective disease response = subjects with confirmed complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target lesions. A PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| participants | Irinotecan + Cisplatin (Cohort 1) | Etoposide + Cisplatin (Cohort 1) | Irinotecan + Cisplatin (Cohort 2) | Etoposide + Cisplatin (Cohort 2) |
|---|---|---|---|---|
| Number of Subjects With Overall Confirmed Response | — | — | 79 | 94 |
OS was defined as the time from date of randomization to date of death due to any cause. For a subject not expiring, the OS time was censored on the last date of contact that they were known to be alive. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.
| months | Irinotecan + Cisplatin (Cohort 2) | Etoposide + Cisplatin (Cohort 2) |
|---|---|---|
| Overall Survival for the Per Protocol (PP) Population | 10.5791 (9.2977 to 12.2875) | 9.4292 (8.5092 to 10.1848) |
DR was defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.
| months | Irinotecan + Cisplatin (Cohort 1) | Etoposide + Cisplatin (Cohort 1) | Irinotecan + Cisplatin (Cohort 2) | Etoposide + Cisplatin (Cohort 2) |
|---|---|---|---|---|
| Duration of Response (DR) | — | — | 5.5195 (4.8953 to 6.1437) | 4.8953 (4.8296 to 5.2895) |
TTP was defined as the time from date of randomization to the date of the first documentation of tumor progression. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.
| months | Irinotecan + Cisplatin (Cohort 1) | Etoposide + Cisplatin (Cohort 1) | Irinotecan + Cisplatin (Cohort 2) | Etoposide + Cisplatin (Cohort 2) |
|---|---|---|---|---|
| Time to Tumor Progression (TTP) | — | — | 5.3552 (4.9281 to 6.2423) | 6.2423 (5.6838 to 6.7023) |
The EORTC QLQ-C30 scales include 5 functional scales (physical, role, cognitive, emotional, and social), a global health status/QL scale and 9 symptom scales: nausea and vomiting, pain, fatigue, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties. All scales and single-item measures range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, for the global health status/QL represents a high QL (better patient state), and for a symptom scale/item represents a high level of symptomatology/problems (worse patient state).
No measurements were reported for this outcome.
Improvement of ≥ 1 tumor related symptom = clinical benefit responder. Pain improvement = decrease of ≥ 1 National Cancer Institute (NCI) grade from baseline of ≥ 1 symptom of NCI pain category, without pain symptom worsening. Cough, dyspnea and hemoptysis improvement = decrease of ≥ 1 NCI grade from baseline. Positive weight change ≥ 5 percent gain from baseline. Positive analgesic consumption = change from baseline from opioid to non-opioid category.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Irinotecan + Cisplatin (Cohort 1) | — | 9/39 (23.1%) | 39/39 (100%) |
| Etoposide + Cisplatin (Cohort 1) | — | 4/38 (10.5%) | 38/38 (100%) |
| Irinotecan + Cisplatin (Cohort 2) | — | 45/202 (22.3%) | 202/202 (100%) |
| Etoposide + Cisplatin (Cohort 2) | — | 29/203 (14.3%) | 203/203 (100%) |
| Event | Irinotecan + Cisplatin (Cohort 1) | Etoposide + Cisplatin (Cohort 1) | Irinotecan + Cisplatin (Cohort 2) | Etoposide + Cisplatin (Cohort 2) |
|---|---|---|---|---|
| FatigueGeneral disorders | 7/39 | 4/38 | 25/202 | 14/203 |
| Diarrhoea NOSGastrointestinal disorders | 5/39 | 1/38 | 33/202 | 5/203 |
| NauseaGastrointestinal disorders | 6/39 | 2/38 | 23/202 | 12/203 |
| Weight decreasedInvestigations | 6/39 | 0/38 | 20/202 | 10/203 |
| Dyspnoea NOSRespiratory, thoracic and mediastinal disorders | 5/39 | 2/38 | 30/202 | 22/203 |
| Vomiting NOSGastrointestinal disorders | 5/39 | 2/38 | 22/202 | 7/203 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/39 | 2/38 | 25/202 | 15/203 |
| Leukopenia NOSBlood and lymphatic system disorders | 3/39 | 1/38 | 10/202 | 5/203 |
| Bone painMusculoskeletal and connective tissue disorders | 3/39 | 1/38 | 7/202 | 8/203 |
| General physical health deteriorationGeneral disorders | 0/39 | 0/38 | 14/202 | 9/203 |
| Event | Irinotecan + Cisplatin (Cohort 1) | Etoposide + Cisplatin (Cohort 1) | Irinotecan + Cisplatin (Cohort 2) | Etoposide + Cisplatin (Cohort 2) |
|---|---|---|---|---|
| FatigueGeneral disorders | 28/39 | 27/38 | 131/202 | 123/203 |
| Dyspnoea NOSRespiratory, thoracic and mediastinal disorders | 21/39 | 22/38 | 134/202 | 139/203 |
| NauseaGastrointestinal disorders | 23/39 | 22/38 | 135/202 | 123/203 |
| NeutropeniaBlood and lymphatic system disorders | 18/39 | 18/38 | 107/202 | 131/203 |
| CoughRespiratory, thoracic and mediastinal disorders | 24/39 | 23/38 | 130/202 | 130/203 |
| AlopeciaSkin and subcutaneous tissue disorders | 14/39 | 22/38 | 78/202 | 103/203 |
| Diarrhoea NOSGastrointestinal disorders | 17/39 | 4/38 | 113/202 | 28/203 |
| Vomiting NOSGastrointestinal disorders | 18/39 | 18/38 | 112/202 | 84/203 |
| Weight decreasedInvestigations | 20/39 | 12/38 | 83/202 | 61/203 |
| AnorexiaMetabolism and nutrition disorders | 16/39 | 11/38 | 81/202 | 66/203 |
| Age, Customized(participants) | Irinotecan + Cisplatin (Cohort 1) | Etoposide + Cisplatin (Cohort 1) | Irinotecan + Cisplatin (Cohort 2) | Etoposide + Cisplatin (Cohort 2) | Total |
|---|---|---|---|---|---|
| 18 to 44 years | 2 | 1 | 11 | 6 | 20 |
| 45 to 64 years | 27 | 24 | 134 | 130 | 315 |
| > = 65 years | 10 | 13 | 57 | 67 | 147 |
| Sex: Female, Male(Participants) | Irinotecan + Cisplatin (Cohort 1) | Etoposide + Cisplatin (Cohort 1) | Irinotecan + Cisplatin (Cohort 2) | Etoposide + Cisplatin (Cohort 2) | Total |
|---|---|---|---|---|---|
| Female | 7 | 7 | 48 | 48 | 110 |
| Male | 32 | 31 | 154 | 155 | 372 |
The record gives a start of Jun 2002, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Etoposide · Cisplatin · Irinotecan